For research use only. Not for therapeutic Use.
BNC105（Cat No.:I005631） is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 <1 nM for DU145, Calu-6, MDA-MB-231 etc.
| Catalog Number | I005631 |
| CAS Number | 945771-74-4 |
| Synonyms | BNC-105;BNC 105 |
| Molecular Formula | C20H20O7 |
| Purity | ≥95% |
| Target | Cytoskeleton |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (7-hydroxy-6-methoxy-2-methyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone |
| InChI | InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3 |
| InChIKey | RADMJHVVIZTENA-UHFFFAOYSA-N |
| SMILES | CC1=C(C2=C(O1)C(=C(C=C2)OC)O)C(=O)C3=CC(=C(C(=C3)OC)OC)OC |
| Reference | </br>1:Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. Bates D, Feris EJ, Danilov AV, Eastman A.Cancer Biol Ther. 2016;17(3):291-9. doi: 10.1080/15384047.2016.1139245. Epub 2016 Jan 30. PMID: 26891146 Free PMC Article</br>2:The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Inglis DJ, Lavranos TC, Beaumont DM, Leske AF, Brown CK, Hall AJ, Kremmidiotis G.Cancer Biol Ther. 2014;15(11):1552-60. doi: 10.4161/15384047.2014.956605. PMID: 25482941 Free PMC Article</br>3:Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. Flynn BL, Gill GS, Grobelny DW, Chaplin JH, Paul D, Leske AF, Lavranos TC, Chalmers DK, Charman SA, Kostewicz E, Shackleford DM, Morizzi J, Hamel E, Jung MK, Kremmidiotis G.J Med Chem. 2011 Sep 8;54(17):6014-27. doi: 10.1021/jm200454y. Epub 2011 Aug 5. PMID: 21774499 Free PMC Article</br>4:BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, O/’Callaghan M, Matthews CA, Flynn B.Mol Cancer Ther. 2010 Jun;9(6):1562-73. doi: 10.1158/1535-7163.MCT-09-0815. Epub 2010 Jun 1. PMID: 20515948 Free Article |
